Handelsavisen
prelaunch
Companies Healthcare 300451.SZ
30
300451.SZ Shenzhen Stock Exchange Advanced Medical Equipment & Technology

B-SOFT Co Ltd

¥3,98
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-39,4 %
ROE
-10,0 %
Net margin
-38,2 %
Debt / equity
0,02
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

B-SOFT Co Ltd is a Chinese company specializing in healthcare equipment, providing products and services in the advanced medical equipment and technology sector.

Business. B-SOFT Co Ltd (300451.SZ) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. Headquartered in China, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target6,37

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
6,37
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
not yet wired
Profitability
-10,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300451.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300451.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    B-SOFT Co Ltd (300451.SZ) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. Headquartered in China, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    B-SOFT's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage profile. However, the company's liquidity is rated as medium, and its free cash flow is negative at -390.36 million CNY, suggesting cash flow constraints. The current ratio of 2.38 implies the company has sufficient current assets to cover its short-term liabilities, but the negative operating cash flow of -21.20 million CNY raises concerns about its ability to sustain operations without external financing.

    Profitability metrics are deeply negative, with a return on equity of -10.02% and a return on assets of -7.61%. These figures are well below the typical performance of companies in the healthcare equipment industry, which usually exhibit positive returns due to high-margin medical device sales and services. The company's operating income is negative at -414.31 million CNY, and its net income is also negative at -401.65 million CNY, indicating a significant loss-making position.

    Geographic and segment exposure data is not available in the provided dataset, but the company's revenue concentration is likely to be within China, given its listing on the Shenzhen Stock Exchange. The absence of disclosed segments limits the ability to assess diversification or growth drivers within the business.

    The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. Historical revenue data shows a total of 1.05 billion CNY in revenue, but the negative operating and net income figures suggest a challenging operating environment. Analysts have assigned a mean price target of 6.37 CNY, with a median of 6.38 CNY, and a strong buy recommendation from two analysts, indicating some optimism despite the company's current financial performance.

    Risk factors include liquidity constraints and the potential for dilution, although the latter is currently rated as low. The company's negative free cash flow and negative operating cash flow increase the risk of needing to raise additional capital, which could lead to equity dilution. The risk assessment also flags that net cash is negative after subtracting total debt, further highlighting the company's financial vulnerability.

    Recent events and filings have not been disclosed in the provided data, so it is not possible to assess any material developments in the company's operations or strategy. The absence of recent transcript data or regulatory filings limits the ability to evaluate management's guidance or strategic direction.

    Key takeaways
    • B-SOFT is operating at a significant loss, with negative net income and operating income.
    • The company has a low debt-to-equity ratio but is experiencing negative free cash flow and operating cash flow.
    • Analysts have a generally positive outlook, with a mean price target of 6.37 CNY and a strong buy recommendation.
    • The company's financial health is constrained by liquidity risks and the potential need for additional capital.
    • There is no disclosed segment or geographic diversification data, limiting visibility into growth drivers.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥3,98
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥4.01B
    Net cash
    -¥75.2M
    Current ratio
    2.4
    Debt / equity
    0.0
    ROA
    -7.6%
    ROE
    -10.0%
    Cash conversion
    5.0%
    CapEx / revenue
    -16.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,01
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-21 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,01
    Revenueno estimateno estimate1,4B CNY
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy2
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price target¥6,37 · Median ¥6,38
    Low ¥6,00High ¥6,71
    EPS surprise
    −5 100,0 %
    reported vs consensus · miss
    Revenue surprise
    −23,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥6,00
    Mean¥6,37
    Median¥6,38
    High¥6,71
    Spot¥3,98
    +60.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-39,4 %Below median
    Net Margin-38,2 %Below median
    ROE-10,0 %Below median
    Capex / Rev-16,4 %Bottom quartile
    D/E0,02Above median
    Cash Conv0,05Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • B-SOFT Co Ltd Market data — financials · 2026-05-26
    • B-SOFT Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300451.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage